Pramipexole
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Pramipexole: Attention deficit-hyperactivity disorder
One-Sentence Summary
Pramipexole is a dopamine agonist originally used to treat restless legs syndrome and Parkinson disease. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but there are no registered clinical trials and only 7 indirectly related publications (reviews, case reports, one Tourette syndrome RCT and mechanistic work). The prediction rests mainly on the model score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Pramipexole is generally known as a D2/D3 dopamine receptor agonist with preferential D3 activity. Its efficacy in Parkinson disease and restless legs syndrome is established, and both conditions respond to dopaminergic stimulation.
ADHD also involves dysregulated dopamine signalling, so a link is plausible. Genetic studies connect the dopamine D4 receptor and the α2A adrenoceptor to ADHD, and one preclinical study examined their interaction. This link is indirect, though, and no ADHD-specific trial was found.
The very high TxGNN score is a model output. The clinical data compiled for this report do not confirm it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22407510 | 2012 | RCT | Movement Disorders | Multicenter placebo-controlled trial of pramipexole in Tourette syndrome, a related neurodevelopmental condition but not ADHD |
| 19412489 | 2006 | Review | Neuropsychiatric Disease and Treatment | Pramipexole is a D3-selective non-ergoline agonist with potential use in restless legs syndrome |
| 18656214 | 2008 | Review | Revue Neurologique | Overview of restless legs syndrome (indirect relevance to ADHD) |
| 24992083 | 2014 | Cohort | Clinical Neuropharmacology | Piribedil vs pramipexole and ropinirole on vigilance in Parkinson disease with daytime sleepiness |
| 34182128 | 2021 | Preclinical/Mechanistic | Pharmacological Research | α2A adrenoceptor and dopamine D4 receptor variants, which are linked to ADHD and impulse-control disorders |
| 37342213 | 2023 | Case report | Frontiers in Pain Research | Remission of chronic low back pain and oral dysesthesia with comorbid ADHD after atomoxetine plus pramipexole |
| 38649244 | 2024 | Case report | BMJ Case Reports | Hypokalaemia from heavy cola consumption in a patient with ADHD taking pramipexole, among other drugs (ADHD incidental) |
India Market Information
There are 20 valid single-ingredient registrations, all oral tablets. The registration records contain no approved-indication text. Main examples:
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 174320 | Pramirol SR 0.26 Tablet | Prolonged-release tablet | Intas Pharmaceuticals Ltd |
| 142322 | Mirapex 3mg Tablet ER | Extended-release tablet | Boehringer Ingelheim |
| 187963 | Remipex 0.5mg Tablet | Tablet | Torrent Pharmaceuticals Ltd |
| 174023 | Pramipex ER 0.375 Tablet | Extended-release tablet | Sun Pharmaceutical Industries Ltd |
| 176515 | Parpex 0.25mg Tablet | Tablet | Zydus Cadila |
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for label safety information.
- Contraindications from the knowledge graph (not label text): These are disease associations in the model’s knowledge graph. They include psychotic disorder, schizophreniform and schizoaffective disorders, orthostatic hypotension, multiple system atrophy, drug-induced dyskinesia, kidney disease, melanoma, sleep apnea syndromes, narcolepsy and central nervous system disease.
- Drug Interactions: 142 interactions were recorded. Those rated Moderate include morphine (including liposomal), opium, cimetidine, metoclopramide, dronabinol and nabilone. Ranitidine is rated Minor.
Conclusion and Next Steps
Decision: Hold
Rationale: The ADHD prediction has a very high model score but no registered clinical trials and no ADHD-specific publications. The retrieved literature is indirect, so the evidence level is L4. The knowledge graph also lists psychiatric and sleep-related conditions among contraindications, which calls for caution in a neuropsychiatric population.
To proceed, the following is needed:
- ADHD-specific clinical or controlled studies of pramipexole
- Detailed mechanism of action data
- Package insert warnings and contraindications for the India products
- A safety assessment of psychiatric, sleep and impulse-control risks in ADHD patients
Note: Among the other TxGNN predictions for pramipexole, schizophrenia has stronger support. It has a Phase 3 add-on trial (NCT01320982, status unknown, no results supplied) and a 2022 placebo-controlled RCT (PMID 35921506). It may merit separate evaluation, with caution because dopamine agonists can worsen psychosis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.